TPSF
CHRS icon

Texas Permanent School Fund’s Coherus Oncology CHRS Stock Holding History

Texas Permanent School Fund’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-58,136
Closed -$248K – 1516
2023
Q2 		$248K Buy
58,136
+956
+2% +$5.64K ﹤0.01% 1507
2023
Q1 		$391K Buy
57,180
+14,029
+33% +$109K ﹤0.01% 1465
2022
Q4 		$342K Sell
43,151
-3,039
-7% -$23.4K 0.01% 1428
2022
Q3 		$444K Buy
46,190
+75
+0.2% +$759 0.01% 1371
2022
Q2 		$334K Buy
46,115
+932
+2% +$8.1K 0.01% 1439
2022
Q1 		$583K Sell
45,183
-766
-2% -$9.74K 0.01% 1352
2021
Q4 		$733K Sell
45,949
-1,008
-2% -$17.6K 0.01% 1310
2021
Q3 		$755K Sell
46,957
-2,721
-5% -$39.9K 0.01% 1303
2021
Q2 		$687K Buy
49,678
+1,820
+4% +$25.8K 0.01% 1335
2021
Q1 		$699K Sell
47,858
-3,051
-6% -$51.8K 0.01% 1319
2020
Q4 		$885K Sell
50,909
-7,839
-13% -$140K 0.01% 1206
2020
Q3 		$1.08M Buy
58,748
+10,565
+22% +$197K 0.01% 1076
2020
Q2 		$861K Buy
+48,183
New +$816K 0.01% 1098

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Texas Permanent School Fund's CHRS Position: Q3 2023 in Review

Texas Permanent School Fund sold out of Coherus Oncology (CHRS) in Q3 2023, closing a stake of 58,136 shares — an estimated $248K sold.

Texas Permanent School Fund first reported a position in CHRS in Q2 2020 and held it in 13 quarters. The position peaked at $1.08M in Q3 2020. 169 funds tracked by Wall St. Rank hold CHRS as of Q3 2023.

  • Texas Permanent School Fund reported no remaining Coherus Oncology position as of Q3 2023 after selling out during the quarter.
  • Texas Permanent School Fund sold 58,136 Coherus Oncology shares in Q3 2023, an estimated $248K.
  • Texas Permanent School Fund first reported a position in Coherus Oncology in Q2 2020 and held it in 13 quarters.
  • Texas Permanent School Fund's Coherus Oncology position peaked at $1.08M in Q3 2020.
  • 169 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2023.

Based on Texas Permanent School Fund's 13F filing for Q3 2023, filed 9 Nov 2023.